Clinical Trial Update: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas [Phase 2]

View source ↗

Summary

Open-label Phase II trial evaluating intravenous BAY80-6946, a PI3K inhibitor, in relapsed or refractory non-Hodgkin lymphoma; the study is completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• BAY80-6946 (BAY-80-6946)

Snippet

Sponsor: Bayer | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2018-01-08